IL32 mRNA levels were significantly higher in anti–PD-1 treatment–responding patients with melanoma or patients with no disease recurrence compared with nonresponders or patients with recurrent disease in 2 independent cohorts (Figure 6, J and K). The gene discussed is IL32; the disease is melanoma.